REGN stock is presently trading nearly 38% lower than its 1-year peak, and is also being traded at a P/S multiple that is ...

Discover why Regeneron Pharmaceuticals, Inc.'s Q3 earnings impress, fueled by Dupixent growth and a robust pipeline. Click ...

Regeneron Pharmaceuticals (REGN) is forecasting annual earnings growth of 7.41%, with revenue also projected to rise by 7% ...

Fintel reports that on October 29, 2025, Guggenheim maintained coverage of Regeneron Pharmaceuticals (NasdaqGS:REGN) with a ...

Regeneron posts Q3 earnings of $11.83 per share, topping estimates as Dupixent profits lift results despite weaker Eylea ...

Fintel reports that on October 29, 2025, Cantor Fitzgerald maintained coverage of Regeneron Pharmaceuticals (NasdaqGS:REGN) ...

Regeneron (REGN) delivered earnings and revenue surprises of +25.32% and +4.38%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Return on Assets (ROA): Regeneron Pharmaceuticals's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 3.67%, the company showcases ...

Longleaf Partners, managed by Southeastern Asset Management, released its “Partners Fund” third-quarter 2025 investor letter.

Currently, the analyst consensus on Regeneron is a Moderate Buy with an average price target of $751.00, representing a 15.02% upside. In a report released yesterday, Canaccord Genuity also maintained ...